About the Pharma AI Council
Artificial Intelligence (AI) has firmly established its value in the Life Sciences industry. From accelerating gene sequencing and optimizing clinical trial design to monitoring market dynamics and empowering sales and medical professionals in the field, AI is driving transformative change—helping bring therapies to market faster to patients waiting in need.
To maximize AI’s potential in this highly regulated space, solutions must not only deliver substantial gains in efficiency and effectiveness, but also maintain strict regulatory compliance.
Recognizing this, the Pharma AI Council (PAC) was founded to guide and empower the software community in delivering AI innovations that truly serve the unique needs of Life Sciences.
MISSION
The mission of PAC is to shape the future of AI in Life Sciences by ensuring its application in commercial workflows is trustworthy, compliant, and impactful.
PAC is committed to driving the responsible use of AI across pharmaceutical, medical device, and biotech companies—accelerating innovation, reducing time and cost to market, and ultimately improving patient outcomes at scale.
PURPOSE
The purpose of PAC is to guide the software industry in building AI solutions that address only the most critical and widespread challenges—those that are urgent, pervasive, and aligned with what the market is willing to invest in solving.
To achieve this, the PAC provides direct feedback and strategic insights to help define and validate high-impact market problems, identify key problem owners, shape compelling use cases, outline core market requirements, and assess industry readiness to pay.
VALUE
The Pharma AI Council (PAC) is a strategic collaboration between pharma, biotech, and med device experts and AI innovators, designed to drive responsible and impactful AI application in Life Sciences. PAC members contribute invaluable insight into real-world market challenges, validate high-impact use cases, and offer candid, experience-based feedback on AI concepts and prototypes. In return, they gain a unique opportunity to shape the future of AI in pharma tech—benefiting from early access to innovation ideas, while expanding their network and elevating their profile as thought leaders in AI. With full confidentiality and a direct line to influence product direction, members get to help shape the future of AI in Life Sciences.
WHY THIS MATTERS
“GenAI is expected to produce $60-110B in annual value across the pharmaceutical industry value chain.”
– McKinsey & Company Survey January 2024
“40% of pharma executives include generative AI savings in their 2024 budgets, and 60% have set targets for cost savings or productivity gains.”
– Bain & Company Survey
February 2024
“69% of pharma commercial teams are increasing budgets for AI-driven analytics, with 79% confident these tools will boost brand performance.”
– Verix Survey
March 2024
Members
Meet the members of PAC—visionary leaders in Life Sciences and torchbearers of innovation.
Bryce Emery King
Kishan Kumar
Adam Latts
Lori Tierney
Amanda Tri
Jennifer Troiano
Joe Wendel
Carl Wooten
Co-chair
Parth Khanna
